NOV 26, 2020 8:25 AM PST

Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin

WRITTEN BY: Jasper Cantrell

Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote heart issues. It stands to reason that perhaps a diabetes drug may be able to treat cardiovascular disease.

That is what a team from the Medical University at Innsbruck in Austria thought. The drug empagliflozin is an inhibitor of a protein called sodium-glucose transporter 2 (SGLT2) and is used to treat type 2 diabetes. Surprisingly, empagliflozin has also shown cardioprotective effects in several studies, leading some to wonder if it could be a preventative drug for cardiovascular disease. This drug is available with discount coupons at PricePro pharmacy online: https://www.pricepropharmacy.com.

The team decided to investigate empagliflozin’s effects as a cardioprotective agent and how it might conduct its protection. The team used a relatively short-term diabetic mouse model for this study, as long-term models can sometimes result in quite variable results.

The expected short-term effects of improved insulin sensitivity were clear from the beginning. Empagliflozin therapy also reduced inflammatory and cardiac fibrosis markers compared to controls. Inflammation can cause blood flow issues in the short term, with fibrosis being a cardiovascular disease where the heart progressively stiffens until heart failure occurs.

The team also observed that a protein marker of mitochondrial mass was upregulated in empagliflozin treated mice. Electron microscopy showed that the mitochondria in the treated mice were markedly different in their structures and size than control diabetic mice. Mitochondria are critical parts of the cell, so any such changes are a big deal.

This short study identified some possible mechanisms by which empagliflozin could act as a cardioprotective agent. The reduced protein inflammatory and fibrosis markers are the clearest sign of the cardioprotective effects of empagliflozin. The mitochondrial effects were interesting, as diabetes often causes abnormal mitochondrial structures. Empagliflozin may alleviate that abnormality to some degree, which could rescue endangered cells (or enable proper cell death if need be). This study wasn’t a comprehensive one, but never the less supplied some idea for future studies to work on.

The study concludes, “Mechanistically, improved mitochondrial ultrastructure, ameliorated over-activation of insulin signaling activity and changed macrophage polarization might contribute to cardioprotective effects of empagliflozin.”

 

Sources: Nature Scientific Reports, MDLinx, Unsplash

About the Author
Bachelors of the Sciences
Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAR 29, 2022
Cardiology
Heart Disease Patients Show Altered Gut Microbiomes
MAR 29, 2022
Heart Disease Patients Show Altered Gut Microbiomes
Two recent studies have linked disturbed gut microbiomes to cardiovascular disease.
MAY 12, 2022
Clinical & Molecular DX
Researchers Show Influenza Directly Infects the Heart
MAY 12, 2022
Researchers Show Influenza Directly Infects the Heart
Heart complications are often observed in severe or fatal cases of Influenza. These problems can include electrical malf ...
MAY 22, 2022
Drug Discovery & Development
Gout Medication Helps Hospitalized People with Heart Failure
MAY 22, 2022
Gout Medication Helps Hospitalized People with Heart Failure
A research team at the University of Virginia Hospital System found that a regularly-used medication for gout, called co ...
MAY 21, 2022
Cardiology
Do E-cigarettes Cause Cardiovascular Disease?
MAY 21, 2022
Do E-cigarettes Cause Cardiovascular Disease?
In the late 1960s, the Public Health Cigarette Smoking Act was introduced by Congress, requiring written warnings to be ...
MAY 24, 2022
Cardiology
Obesity in Pregnancy Increases Child's Risk of Heart Disease
MAY 24, 2022
Obesity in Pregnancy Increases Child's Risk of Heart Disease
Obesity and unhealthy diets cause gene expression changes that negatively impact the cardiac function of offspring.
AUG 02, 2022
Cardiology
Exercising 150-600 Minutes Per Week Leads to Lowest Death Risk
AUG 02, 2022
Exercising 150-600 Minutes Per Week Leads to Lowest Death Risk
People who exercise for two to four times the recommended amount per week see major reductions in all-cause mortality.
Loading Comments...